Table 1. Model parameters used to assess the pharmaceutical forecast

	France	Germany	Greece	Hungary	Poland	Portugal	United Kingdom
Brands
Time to market after marketing authorization (months)	12	0	12	12	12	12	12
Generics: retail chain
Time to market after marketing authorization (days)	60	0	270	45	180	150	0
Price reduction of the generic versus the original branded product (%)	60	55	60	55	45	60	75
Generic penetration (generics and off-patent brands): volume uptake (%)	80	85	25	100	85	25	80
Time to reach maximum of generic penetration (months)	36	12	36	18	24	30	12
Impact of generic entry on brand price (%)	20	0	50	0	25	0	0
Generics and biosimilars: hospital chain
Time to market after marketing authorization (days)	0	0	0	0	0	0	0
Price reduction of the generic or biosimilar versus the original branded product (%)	80	80	80	80	80	80	80
Generic and biosimilar penetration (generic, biosimilar, and off-patent brands): volume uptake (%)	100	100	100	100	100	100	100
Time to reach maximum of generic or biosimilar penetration (months)	0	0	0	0	0	0	0
Impact of generic or biosimilar entry on brand price (%)	0	0	0	0	0	0	0
Biosimilars: retail chain
Time to market after marketing authorization (days)	470	180	450	580	540	530	180
Price reduction of the biosimilar versus the original branded product (%)	30	25	25	50	45	30	25
Biosimilar penetration (biosimilar and off-patent brands): volume uptake (%)	15	25	5	100	25	15	15
Time to reach maximum of biosimilar penetration (months)	36	12	36	18	24	30	12
Impact of biosimilar entry on brand price (%)	10	0	25	0	12	0	0
Reimbursement
Reimbursement rates (%)	69	90	80	67	62.5	81.6	100